There are 2867 resources available
985P - Tepotinib outcomes according to prior therapies in patients with MET exon 14 (METex14) skipping NSCLC
Presenter: Egbert Smit
Session: Poster session 14
987P - Sunvozertinib for NSCLC patients with EGFR exon 20 insertion mutations: Preliminary analysis of WU-KONG6, the first pivotal study
Presenter: Mengzhao Wang
Session: Poster session 14
988P - Phase I/II study of mobocertinib in EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): Updated results from platinum-pretreated patients (PPP)
Presenter: Suresh Ramalingam
Session: Poster session 14
989P - Sotorasib in advanced KRAS p.G12C-mutated non-small cell lung cancer (NSCLC): Safety and efficacy data from the global expanded access program (EAP)
Presenter: Mark Awad
Session: Poster session 14
990P - Osimertinib for RT-naïve CNS metastasis of EGFR mutation-positive NSCLC: Phase II OCEAN study (LOGIK 1603/WJOG 9116L), part of the first-line cohort
Presenter: Hiroyuki Yamaguchi
Session: Poster session 14
991P - EGFR exon 20 insertions in non-small cell lung cancer (NSCLC): Impact of TP53 mutation status and value of immune checkpoint blockade (ICB)
Presenter: Anna Kron
Session: Poster session 14
992P - Updated analyses from the CROWN study of first-line lorlatinib vs crizotinib in Asian patients with ALK-positive non-small cell lung cancer (NSCLC)
Presenter: Zhou Qing
Session: Poster session 14
994P - Efficacy and safety of capmatinib plus spartalizumab in treatment-naïve patients with advanced NSCLC harboring MET exon 14 skipping mutation
Presenter: Jürgen Wolf
Session: Poster session 14
995P - Effectiveness of combination of osimertinib with another targeted therapy in advanced EGFR mutated non-small cell lung cancer harbouring other oncogenic drivers: The real-world COMPOSIT study
Presenter: Camille Mehlman
Session: Poster session 14